Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov;3(1 Suppl):S21-35.
doi: 10.1177/1758834011422557.

c-MET as a potential therapeutic target and biomarker in cancer

J Rafael Sierra  1 , Ming-Sound Tsao
Affiliations

c-MET as a potential therapeutic target and biomarker in cancer

J Rafael Sierra et al. Ther Adv Med Oncol. 2011 Nov.

Abstract

The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.

Keywords: c-MET; cancer; hepatocyte growth factor; personalized medicine; targeted therapy.

PubMed Disclaimer

References

    1. Aguirre Ghiso J.A., Alonso D.F., Farias E.F., Gomez D.E., de Kier Joffe E.B. (1999) Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 263: 295–304 - PubMed
    1. Amgen (2008) Panitumumab combination study with AMG 102 or AMG 479 in wild-type KRAS mCRC. National Clinical Trial NCT00788957. Available at: http://clinicaltrials.gov/ct2/show/NCT00788957 (accessed 18 August 2011).
    1. Argast G.M., Croy C.H., Couts K.L., Zhang Z., Litman E., Chan D.C., et al. (2009) Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene 28: 2697–2709 - PMC - PubMed
    1. Aune G., Lian A.M., Tingulstad S., Torp S.H., Forsmo S., Reseland J.E., et al. (2011) Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol 121: 402–406 - PubMed
    1. Barakat O., Rodriguez G.C., Raijman I., Allison P.M., Nieto J., Ozaki C.F., et al. (2010) Clinical value of plasma hepatocyte growth factor measurement for the diagnosis of periampullary cancer and prognosis after pancreaticoduodenectomy. J Surg Oncol 102: 816–820 - PubMed